Advanced Search
MyIDEAS: Login to save this paper or follow this series

Investigating Generic And Brand Name Pharmaceutical’S Market Shares And Prices In Tunisia

Contents:

Author Info

  • Ines Ayadi
  • Houssem Eddine Chebbi

    ()
    (Faculty of Economic Sciences and Management of Nabeul, Tunisia)

  • Younes Boujelbene

Abstract

The purpose of this paper is to investigate how the brand name’s market shares in Tunisia are affected by generic competition during the pre-reform period of the Tunisian health insurance system following the methodological approach developed by Aronsson et al. (2001). In this study we use data for three molecules Captopril (antihypertensive) Glibenclamide (antidiabetic) and Carbamazepine (antiepileptic) from IMS Health database. The data span from the third quarter 2002 to second quarter 2007. Statistical results indicate that the impact of generic competition seems to be not different across markets (Captopril, Glibenclamide and Carbamazepine) in Tunisia. In addition, the relative price has a positive and significant effect on the change of market share of the brand name drug in Tunisia for the three active molecules. The higher the price of the brand name product relative to the average price of the generic substitutes, the smaller the decrease of market share of the brand name product. In Tunisian pharmaceutical market, brand- names charge a higher price than their generic versions and still obtain positive market shares. Thus, from a policy perspective, the large market share of higher priced brand-names relative to their generic versions is an unsatisfactory outcome taking into account that brand name drug and generics are identical products and provide similar health gains to patients.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://www.erf.org.eg/CMS/getFile.php?id=1474
Our checks indicate that this address may not be valid because: 500 Can't connect to www.erf.org.eg:80 (10060). If this is indeed the case, please notify (Namees Nabeel)
Download Restriction: no

File URL: http://www.erf.org.eg/cms.php?id=NEW_publication_details_working_papers&publication_id=1135
Our checks indicate that this address may not be valid because: 500 Can't connect to www.erf.org.eg:80 (10060). If this is indeed the case, please notify (Namees Nabeel)
Download Restriction: no

Bibliographic Info

Paper provided by Economic Research Forum in its series Working Papers with number 497.

as in new window
Length: 13 pages
Date of creation: Jul 2009
Date of revision: Jul 2009
Publication status: Published by The Economic Research Forum (ERF)
Handle: RePEc:erg:wpaper:497

Contact details of provider:
Postal: 7 Boulos Hanna Street, Dokki, Cairo
Phone: 202-3370810
Fax: 202-3616042
Email:
Web page: http://www.erf.org.eg
More information through EDIRC

Related research

Keywords:

Other versions of this item:

Find related papers by JEL classification:

References

References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
as in new window
  1. Danzon, Patricia M & Chao, Li-Wei, 2000. "Does Regulation Drive out Competition in Pharmaceutical Markets?," Journal of Law and Economics, University of Chicago Press, vol. 43(2), pages 311-57, October.
  2. Judith K. Hellerstein, 1998. "The Importance of the Physician in the Generic Versus Trade-Name Prescription Decision," RAND Journal of Economics, The RAND Corporation, vol. 29(1), pages 108-136, Spring.
  3. Joan Costa-Font & Panos Kanavos & Joan Rovira, 2007. "Determinants of out-of-pocket pharmaceutical expenditure and access to drugs in Catalonia," Applied Economics, Taylor & Francis Journals, vol. 39(5), pages 541-551.
  4. Nina Pavcnik, 2002. "Do Pharmaceutical Prices Respond to Potential Patient Out-of-Pocket Expenses?," RAND Journal of Economics, The RAND Corporation, vol. 33(3), pages 469-487, Autumn.
  5. Richard G. Frank & David S. Salkever, 1997. "Generic Entry and the Pricing of Pharmaceuticals," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 6(1), pages 75-90, 03.
  6. Dranove, David, 1989. "Medicaid Drug Formulary Restrictions," Journal of Law and Economics, University of Chicago Press, vol. 32(1), pages 143-62, April.
  7. Richard G. Frank & David S. Salkever, 1995. "Generic Entry and the Pricing of Pharmaceuticals," NBER Working Papers 5306, National Bureau of Economic Research, Inc.
Full references (including those not matched with items on IDEAS)

Citations

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:erg:wpaper:497. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Namees Nabeel).

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.